FDA Drug recall D-1618-2020
Nature Throid, 2 Grain (130 mg) Thyroid USP [Liothyronine (T3) 18 mcg, Levothyroxine (T4) 76 mcg], packaged in a) 30-count bottles (NDC 647…
- FDA Drug
- Class I
- terminated
- Published 2020-09-23
On 2020-09-23 the FDA classified a Class I recall of Nature Throid, 2 Grain (130 mg) Thyroid USP [Liothyronine (T3) 18 mcg, Levothyroxine (T4) 76 mcg], packaged in a) 30-count bottles (NDC 647… by Rlc Labs, citing subpotent Drug: FDA analysis found product to be subpotent.
Read the official FDA Drug notice
| Agency | FDA Drug |
|---|---|
| Recall number | D-1618-2020 |
| Classification | Class I |
| Status | terminated |
| Initiated | 2020-08-25 |
| Published | 2020-09-23 |
| Last updated | 2026-09-13 11:52 UTC |
| Company | Rlc Labs |
| Distribution | US |
Product
Nature Throid, 2 Grain (130 mg) Thyroid USP [Liothyronine (T3) 18 mcg, Levothyroxine (T4) 76 mcg], packaged in a) 30-count bottles (NDC 64727-3308-4) and b)100-count bottles (NDC 64727-3308-1), Rx only, Manufactured by: RLC Labs Phoenix, AZ 85024
Reason
Subpotent Drug: FDA analysis found product to be subpotent
Identifiers
| code_info | Lot #: 109264, Exp. Date 10/2022 |
|---|
Status history
No status changes recorded since RecallRadar first saw this recall on 2026-09-13 11:52 UTC. Current status: terminated.
Source
Official record: https://api.fda.gov/drug/enforcement.json?search=recall_number:%22D-1618-2020%22
RecallRadar indexes public recall notices from the FDA, USDA FSIS, and CPSC. The official agency notice is the authoritative source. Always confirm details at the linked source before acting.